![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Utilization Patterns and HIV Incidence Within the First Year of Initiation of TDF/FTC for HIV Pre-exposure Prophylaxis (PrEP) Among Insured Individuals in the US
|
|
|
HIVR4P 2021 (Virtual event); 27-28 January & 3-4 February 2021
Reported by Jules Levin
Yohance Whiteside1; Tania Gulati2; Marco Mesa-frias1; Niranjan Kathe2; Kirti Mirchandani2; Riddhi Markan2; Akanksha Singh2
1Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA; 2Complete Health Economics and Outcomes Research Solutions, North Wales, PA, USA
![0127211](../images/012721/012721-9/0127211.gif)
![0127212](../images/012721/012721-9/0127212.gif)
![0127213](../images/012721/012721-9/0127213.gif)
![0127214](../images/012721/012721-9/0127214.gif)
![0127215](../images/012721/012721-9/0127215.gif)
![0127216](../images/012721/012721-9/0127216.gif)
![0127217](../images/012721/012721-9/0127217.gif)
![0127218](../images/012721/012721-9/0127218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|